Manipulating a protein to control HIV latency
Controlling HIV latency by manipulating CycT1 turnover
This study is looking at ways to boost a protein called CycT1 in immune cells to help fight HIV and related cancers, focusing on how to keep this protein stable in resting immune cells, which could lead to better treatments for people living with HIV.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Francisco NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project ID | NIH-10883698 on NIH RePORTER |
What this research studies
This research investigates how to increase the levels of a protein called CycT1 in immune cells, which is crucial for fighting HIV and related cancers. The study focuses on understanding the mechanisms that lead to the down-regulation of CycT1 in resting CD4+ T cells, which are key reservoirs for HIV. By identifying the cellular pathways that regulate the stability of CycT1, the researchers aim to enhance immune responses and potentially reactivate latent HIV. This could lead to improved treatments for individuals living with HIV and associated malignancies.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals living with HIV who have experienced immune dysfunction or are at risk for AIDS-related cancers.
Not a fit: Patients who are HIV-negative or do not have any associated immune dysfunction or cancers may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new strategies for reactivating latent HIV and enhancing immune responses against HIV-related cancers.
How similar studies have performed: Other research has shown promise in manipulating cellular pathways to enhance immune responses, suggesting that this approach could be effective.
Where this research is happening
San Francisco, United States
- University of California, San Francisco — San Francisco, United States (Active)
Researchers
- Principal investigator: Fujinaga, Koh — University of California, San Francisco
- Study coordinator: Fujinaga, Koh
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.